Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Study finds no standard for treatment discontinuation in myeloma

Publish date:: October 1, 2019

Key clinical point: There is no standard for treatment discontinuation in multiple myeloma.

Major finding: The duration of therapy and time to next treatment were shorter in this study than in clinical trials, and reasons for treatment discontinuation varied by regimen and line of therapy.

Study details: An observational study of 3,201 multiple myeloma patients.

Disclosures: The study is sponsored by Takeda. Dr. Weisel reported relationships with Takeda and several other companies.

Citation:

Weisel K et al. IMW 2019, Abstract OAB-005.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lymphoma & Plasma Cell Disorders

Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplant,

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Study found dual-targeted CAR T highly active against relapsed/refractory multiple myeloma,

Phase 1 study shows feasibility, safety, efficacy of STAR T cells for ALL,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,